2021 IPO
Caribou Biosciences Stock
Biotechnology company specializing in genome engineering
Sign up today and learn more about Caribou Biosciences Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Caribou Biosciences Stock
Caribou Biosciences is a biotechnology company in genome engineering. We develop technology-based solutions for cellular engineering and analysis based on the CRISPR-Cas9 technology platform. Cas9, when paired with a guide RNA, cuts double-stranded DNA allowing for specific changes to DNA. These site-specific DNA modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins.
Investors
F-Prime Capital Partners
PharmEasy, Devoted Health, Benchling, SonderMind, Prime Medicine, Snapdocs, Flywire, Quartet, Caribou Biosciences, Unison Home Ownership Investors
Heritage Group
Actifio, Reputation.com, Factual, ClearDATA, Caribou Biosciences
Anterra Capital
Novartis
Pontifax AgTech
Funding History
October 2014 | $2.9M |
---|---|
March 2015 | $11.5M |
May 2016 | $30.0M |
May 2016 | $30.1M |
Management
Co-Founder
Jennifer A. Doudna
Co-Founder
James Berger
Chief Scientific Officer
Andy May
Press
businesswire - Sep, 26 2019
Caribou Biosciences announces that JAMS panel issued Interim Award in the arbitration with Intellia Therapeuticsbusinesswire - Feb, 12 2019
Caribou Biosciences Announces Expansion of Scientific Advisory BoardTechCrunch - Sep, 4 2018
These two CRISPR experts are coming to Disrupt SF 2018Business Wire (press release) - May, 3 2018
Caribou Biosciences Appoints Timothy F. Herpin, Ph.D. as Chief Business OfficerOZY - Mar, 16 2018
This Scientist Turned CEO Wants to Gene-Edit a Way to Cure Cancer